Stocks and Investing
by (remove) : Keay Nakae
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Keay Nakae
RSSJSONXMLCSV
Fri, August 23, 2024
Thu, August 22, 2024
Wed, July 17, 2024
Wed, June 26, 2024
Wed, June 5, 2024
Mon, June 3, 2024
Tue, May 28, 2024
Wed, May 15, 2024
Fri, May 10, 2024
Fri, May 3, 2024
Thu, April 4, 2024
Fri, March 1, 2024
Fri, February 16, 2024
Thu, February 15, 2024
Fri, February 9, 2024
Wed, August 16, 2023
Fri, August 11, 2023
Tue, August 8, 2023
Fri, August 4, 2023
Thu, June 22, 2023
Tue, June 6, 2023
Fri, June 2, 2023
Wed, May 24, 2023
Thu, May 11, 2023
Wed, April 19, 2023
Thu, March 30, 2023
Fri, March 3, 2023
Fri, February 24, 2023

Keay Nakae Maintained (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024


Published on 2024-10-28 13:51:04 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024.

Keay has made no other calls on SONN in the last 4 months.



There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Keay's Rating of Hold.



This is the rating of the analyst that currently disagrees with Keay


  • Tim Moore of "EF Hutton" Maintained at Strong Buy with Decreased Target to $56 on, Thursday, May 16th, 2024
Contributing Sources